Convection-enhanced delivery of a transforming growth factor-beta2 inhibitor trabedersen for recurrent high-grade gliomas: efficacy real or imagined?, in reference to Bogdahn et al. (Neuro-Oncology 2011;13:132-142)

Comment

Marc C Chamberlain. Neuro Oncol. 2011 May.

. 2011 May;13(5):558-9; author reply 561-2.

doi: 10.1093/neuonc/nor048.

No abstract available

Comment on

Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study.
Bogdahn U, Hau P, Stockhammer G, Venkataramana NK, Mahapatra AK, Suri A, Balasubramaniam A, Nair S, Oliushine V, Parfenov V, Poverennova I, Zaaroor M, Jachimczak P, Ludwig S, Schmaus S, Heinrichs H, Schlingensiepen KH; Trabedersen Glioma Study Group. Bogdahn U, et al. Neuro Oncol. 2011 Jan;13(1):132-42. doi: 10.1093/neuonc/noq142. Epub 2010 Oct 27. Neuro Oncol. 2011. PMID: 20980335 Free PMC article. Clinical Trial.

1. Bogdahn U, Stockhammer G, Venkataramana AK, et al. Targeted therapy for high grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro Oncol. 2011;13:132–142. - PMC - PubMed
1. Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999;17:2572–2578. - PubMed
1. Lamborn KR, Yung WK, Chang SM, et al. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol. 2008;10:162–170. - PMC - PubMed
1. Wick WW, Weller M Neuro-oncology Working Group of the German Cancer Society. NOA-04 randomized Phase III study of sequential radiochemotherapy of oligoastrocytic tumors of WHO-grade III with PCV or temozolomide. J Clin Oncol. 2010;28(15S):5874–80.